Management of endometriosis with nor-progesterone
article
OA: closed
CC0
⤵ 6 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This paper examines the management of endometriosis using nor-progesterone, a synthetic progestin.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (3)
- A correlative study of adenomyosis and pelvic endometriosis, with special reference to the hormonal reaction of ectopic endometrium via openalex
- Effects of Progestin-Induced Pseudopregnancy on Endometriosis: Clinical and Microscopic Studies via openalex
- The use of newer progestins in the treatment of endometriosis via openalex
Cited by (6)
- Gestogens and anti-gestogens as treatment of endometriosis 1991
- Endometriosis 1984
- The prevention, inhibition, palliation, and treatment of endometriosis 1975
- Die therapeutische Anwendung der Gestagene beim Menschen 1968
- The Effects of New Synthetic Progestogens on Endometriosis in the Human Female 1965
- Effects of progesterone and norethindrone on experimental endometriosis in monkeys 1962
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-14T05:59:39.616318+00:00
License: CC0
· commercial use OK